Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma - PubMed (original) (raw)
. 2005 Apr 1;23(10):2280-99.
doi: 10.1200/JCO.2005.06.104.
Michael Baudis, Katleen De Preter, Nadine Van Roy, Peter Ambros, Nick Bown, Christian Brinkschmidt, Holger Christiansen, Valérie Combaret, Maria Lastowska, James Nicholson, Anne O'Meara, Dominique Plantaz, Raymond Stallings, Bénédicte Brichard, Caroline Van den Broecke, Sylvia De Bie, Anne De Paepe, Geneviève Laureys, Frank Speleman
Affiliations
- PMID: 15800319
- DOI: 10.1200/JCO.2005.06.104
Free article
Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma
Jo Vandesompele et al. J Clin Oncol. 2005.
Free article
Abstract
Purpose: Neuroblastoma is a genetically heterogeneous pediatric tumor with a remarkably variable clinical behavior ranging from widely disseminated disease to spontaneous regression. In this study, we aimed for comprehensive genetic subgroup discovery and assessment of independent prognostic markers based on genome-wide aberrations detected by comparative genomic hybridization (CGH).
Materials and methods: Published CGH data from 231 primary untreated neuroblastomas were converted to a digitized format suitable for global data mining, subgroup discovery, and multivariate survival analyses.
Results: In contrast to previous reports, which included only a few genetic parameters, we present here for the first time a strategy that allows unbiased evaluation of all genetic imbalances detected by CGH. The presented approach firmly established the existence of three different clinicogenetic subgroups and indicated that chromosome 17 status and tumor stage were the only independent significant predictors for patient outcome. Important new findings were: (1) a normal chromosome 17 status as a delineator of a subgroup of presumed favorable-stage tumors with highly increased risk; (2) the recognition of a survivor signature conferring 100% 5-year survival for stage 1, 2, and 4S tumors presenting with whole chromosome 17 gain; and (3) the identification of 3p deletion as a hallmark of older age at diagnosis.
Conclusion: We propose a new regression model for improved patient outcome prediction, incorporating tumor stage, chromosome 17, and amplification/deletion status. These findings may prove highly valuable with respect to more reliable risk assessment, evaluation of clinical results, and optimization of current treatment protocols.
Similar articles
- Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome.
Brinkschmidt C, Christiansen H, Terpe HJ, Simon R, Lampert F, Boecker W, Dockhorn-Dworniczak B. Brinkschmidt C, et al. Med Pediatr Oncol. 2001 Jan;36(1):11-3. doi: 10.1002/1096-911X(20010101)36:1<11::AID-MPO1004>3.0.CO;2-M. Med Pediatr Oncol. 2001. PMID: 11464859 - Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma.
Spitz R, Hero B, Simon T, Berthold F. Spitz R, et al. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3368-73. doi: 10.1158/1078-0432.CCR-05-2495. Clin Cancer Res. 2006. PMID: 16740759 - Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma.
Bown N, Cotterill S, Lastowska M, O'Neill S, Pearson AD, Plantaz D, Meddeb M, Danglot G, Brinkschmidt C, Christiansen H, Laureys G, Speleman F, Nicholson J, Bernheim A, Betts DR, Vandesompele J, Van Roy N. Bown N, et al. N Engl J Med. 1999 Jun 24;340(25):1954-61. doi: 10.1056/NEJM199906243402504. N Engl J Med. 1999. PMID: 10379019 - Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
Warnat P, Oberthuer A, Fischer M, Westermann F, Eils R, Brors B. Warnat P, et al. BMC Cancer. 2007 May 25;7:89. doi: 10.1186/1471-2407-7-89. BMC Cancer. 2007. PMID: 17531100 Free PMC article. Review. - Neuroblastoma 4S: a heterogeneous disease with variable risk factors and treatment strategies.
van Noesel MM, Hählen K, Hakvoort-Cammel FG, Egeler RM. van Noesel MM, et al. Cancer. 1997 Sep 1;80(5):834-43. Cancer. 1997. PMID: 9307181 Review.
Cited by
- Multiple Genes with Potential Tumor Suppressive Activity Are Present on Chromosome 10q Loss in Neuroblastoma and Are Associated with Poor Prognosis.
Ognibene M, De Marco P, Amoroso L, Cangelosi D, Zara F, Parodi S, Pezzolo A. Ognibene M, et al. Cancers (Basel). 2023 Mar 29;15(7):2035. doi: 10.3390/cancers15072035. Cancers (Basel). 2023. PMID: 37046696 Free PMC article. - Chromosome instability in neuroblastoma: A pathway to aggressive disease.
Paolini L, Hussain S, Galardy PJ. Paolini L, et al. Front Oncol. 2022 Oct 20;12:988972. doi: 10.3389/fonc.2022.988972. eCollection 2022. Front Oncol. 2022. PMID: 36338721 Free PMC article. Review. - Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma.
Keller KM, Eleveld TF, Schild L, van den Handel K, van den Boogaard M, Amo-Addae V, Eising S, Ober K, Koopmans B, Looijenga L, Tytgat GAM, Ylstra B, Molenaar JJ, Dolman MEM, van Hooff SR. Keller KM, et al. Front Oncol. 2022 Sep 27;12:929123. doi: 10.3389/fonc.2022.929123. eCollection 2022. Front Oncol. 2022. PMID: 36237330 Free PMC article. - Risk factors associated with metastatic site failure in patients with high-risk neuroblastoma.
Lucas JT Jr, Wakefield DV, Doubrovin M, Li Y, Santiago T, Federico SM, Merchant TE, Davidoff AM, Krasin MJ, Shulkin BL, Santana VM, Lee Furman W. Lucas JT Jr, et al. Clin Transl Radiat Oncol. 2022 Mar 10;34:42-50. doi: 10.1016/j.ctro.2022.02.009. eCollection 2022 May. Clin Transl Radiat Oncol. 2022. PMID: 35345864 Free PMC article. - From DNA Copy Number Gains and Tumor Dependencies to Novel Therapeutic Targets for High-Risk Neuroblastoma.
Decaesteker B, Durinck K, Van Roy N, De Wilde B, Van Neste C, Van Haver S, Roberts S, De Preter K, Vermeirssen V, Speleman F. Decaesteker B, et al. J Pers Med. 2021 Dec 3;11(12):1286. doi: 10.3390/jpm11121286. J Pers Med. 2021. PMID: 34945759 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical